Peter Johnson, MD
Neurology · Houston, TXNPI 1154764728
Payments from drug & device makers
Across 86 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$583
- AstraZeneca$284
- Acadia Pharmaceuticals Inc$141
- GE HealthCare$133
- Novartis$91
- Genentech USA, Inc.$68
- plus $480 from 18 others
What the payments were for
- Speaking & faculty fees$241%
- Food & beverage$1,75699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $583 |
| AstraZeneca | 17 | $284 |
| Acadia Pharmaceuticals Inc | 7 | $141 |
| GE HealthCare | 4 | $133 |
| Novartis | 4 | $91 |
| Genentech USA, Inc. | 3 | $68 |
| Boston Scientific | 1 | $50 |
| Johnson & Johnson | 1 | $47 |
| Acorda Therapeutics, Inc | 2 | $41 |
| Bausch Health US, LLC | 2 | $38 |
| Grifols USA, LLC | 1 | $29 |
| UCB, Inc. | 1 | $28 |
| Assertio Therapeutics, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Abbott | 1 | $24 |
| Amgen | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| CSL Behring | 1 | $21 |
| Medtronic | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Biogen | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
How this compares
$1,780 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 33 | $2,031 |
| Levetiracetam | 32 | $836 |
| Pyridostigmine Bromide | 11 | $182 |
| Prednisone | 22 | $60 |
Paid to pharmacies, not to this prescriber.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Mazen DimachkieHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.